potassium oxonate

used to induce hyperuricemia in mice
Networked: 74 relevant articles (2 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Kong, Ling-Dong: 5 articles (01/2015 - 01/2010)
2. Shirao, Kuniaki: 4 articles (11/2009 - 12/2003)
3. Huang, Chi-Chang: 3 articles (01/2015 - 09/2010)
4. Tung, Yu-Tang: 3 articles (01/2015 - 09/2010)
5. Chen, Guang-Liang: 3 articles (01/2014 - 01/2006)
6. Wang, Xing: 3 articles (05/2013 - 01/2010)
7. Ichinose, Yukito: 3 articles (05/2010 - 12/2004)
8. Haidari, Fatemeh: 3 articles (11/2009 - 07/2008)
9. Wu, Jyh-Horng: 2 articles (01/2015 - 01/2012)
10. Ho, Shang-Tse: 2 articles (01/2015 - 01/2012)

Related Diseases

1. Colorectal Neoplasms (Colorectal Cancer)
06/01/1996 - "The purpose of this study was to establish a nude rat orthotopic (organ-specific) human colorectal cancer model as an in vivo secondary screen for general evaluation of new anticancer agents against colorectal cancer and to evaluate practically the antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1), a new p.o. "
06/01/2004 - "The goal of the current study was to evaluate the objective response rate and toxicity associated with the oral fluoropyrimidine S-1 (a combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) in patients with previously untreated metastatic colorectal carcinoma. "
09/01/2010 - "We therefore planned an open-label randomised controlled trial to verify the non-inferiority of irinotecan plus oral S-1 (a combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate; IRIS) to FOLFIRI as second-line chemotherapy for metastatic colorectal cancer. "
09/01/2007 - "The safety and efficacy of combination therapy with 7-ethyl-10-[4-[1-piperidino]-1-piperidino]carbonyloxycamptothecin (CPT-11, irinotecan) and S-1 composed of tegafur, a prodrug of 5-fluorouracil, gimeracil, and potassium oxonate, have been confirmed in patients with colorectal cancer. "
08/18/2008 - "In this study, we examined the antitumor activity of 5-Fluorouracil (5-FU)-based drugs (S-1 [1M tegafur, 0.4M 5-chloro-2,4-dihydroxypyridine and 1M potassium oxonate] and capecitabine) on human colorectal cancer xenografts and evaluated their anti-angiogenic effects. "
2. Neoplasms (Cancer)
3. Hyperuricemia
4. Stomach Neoplasms (Stomach Cancer)
06/01/2004 - "This study demonstrated that, compared with daily administration, alternate-day administration of TS-1 reduces adverse effects, and simultaneously ensures effective blood levels and provides sufficient clinical effects.TS-1 (1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyrimidine-1 M potassium oxonate) has a high single-agent response rate, of more than 40%, for gastric cancer; however, the recommended regimen of 4 weeks of administration interrupted by 2 weeks of drug withdrawal frequently causes adverse effects. "
06/01/2011 - "To evaluate the efficacy, safety and pharmacokinetic profiles of S-1, which composed of tegafur (FT, a prodrug of 5-FU), 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), in Taiwanese advanced gastric cancer (AGC) patients. "
10/01/2012 - "The study is to investigate the pharmacokinetics of S-1 capsule (tegafur, gimeracil and potassium oxonate capsule) in patients with advanced gastric cancer after single and multiple oral administration. "
01/01/2010 - "In this study, we compared the pharmacokinetic profiles of 5-fluorouracil (5-FU), tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) after administration of S-1 at 35 or 40 mg/m(2) bid for 28 consecutive days, in Cycles 1 and 3, in patients with advanced gastric cancer. "
12/01/2003 - "S-1 is an oral fluoropyrimidine derivative combining tegafur with the modulators 5-chloro-2,4-dihydroxypyrimidine (a potent dihydropyrimidine dehydrogenase inhibitor), and potassium oxonate (an orotate phosphoribosyl transferase inhibitor), in a molar ratio of 1 : 0.4 : 1. S-1 has a high response rate, of about 40%, in advanced gastric cancer. "
5. Inflammation

Related Drugs and Biologics

1. Tegafur
2. gimeracil
3. Fluorouracil (Carac)
4. Uracil
5. Uric Acid (Urate)
6. Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)
7. Cisplatin (Platino)
8. titanium silicide (TS-1)
9. irinotecan (Camptosar)
10. Saponins

Related Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)
2. Drug Therapy (Chemotherapy)
3. Oral Administration
4. Adjuvant Chemotherapy
5. Colostomy